TAK

Takeda Pharmaceutical Co Ltd: Q1 FY2026 Earnings Summary

Business Context and Reporting Period

This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2026 (Q1 FY2026). The company operates as a single segment focused on the research, development, manufacturing, and marketing of pharmaceutical products. Results are presented under International Financial Reporting Standards (IFRS).

Key Financial Metrics

Balance Sheet & Liquidity: Total assets stood at JPY 15,663.3 billion as of June 30, 2026. Total equity was JPY 7,558.9 billion, with an equity ratio of 48.3%. Cash and cash equivalents decreased to JPY 461.0 billion. Total bonds and loans were JPY 4,940.0 billion.

Cash Flow: Net cash from operating activities was JPY 127.6 billion, a decrease of JPY 87.8 billion year-over-year, primarily due to increased trade receivables. Net cash used in investing activities was JPY 87.7 billion, and net cash used in financing activities was JPY 180.3 billion.

Material Changes vs. Prior Period

• Revenue Growth: Reported revenue increased 10.2% on an actual exchange rate (AER) basis, driven primarily by the depreciation of the Japanese yen. On a constant exchange rate (CER) basis, revenue declined 0.5%.
• Profitability Pressure: While operating profit rose 9.1% (AER), net profit fell 8.9% (AER) due to a significant increase in income tax expenses (+87.7% AER) and higher restructuring costs.
• Expense Increases:
  • Restructuring: Other operating expenses surged 96.8% (AER) due to a JPY 35.8 billion increase in restructuring expenses related to the transformation program.
  • R&D: R&D expenses increased 16.3% (AER), driven by FX impacts and late-stage pipeline programs (elritercept, TAK-928, TAK-921).
  • Taxes: Income tax expenses rose sharply due to the reassessment of Deferred Tax Assets recoverability and higher U.S. international tax provisions.
• Product Performance:
  • GI: ENTYVIO sales grew 15.4% (AER), driven by subcutaneous formulation uptake.
  • Rare Diseases: TAKHZYRO sales grew 8.7% (AER) despite U.S. competition; LIVTENCITY and VONVENDI showed strong growth.
  • Oncology: ADCETRIS sales increased 30.3% (AER), led by Latin America demand.
  • Neuroscience: VYVANSE/ELVANSE sales declined 6.5% (AER) due to generic erosion in the U.S.

Guidance, Outlook, and Risks

Full Year FY2027 Forecast (Unrevised):

• Revenue: JPY 4,640 billion (+3.0% YoY).
• Operating Profit: JPY 420 billion.
• Net Profit: JPY 166 billion.
• Core Operating Profit: JPY 1,160 billion (-1.1% YoY).
• Core EPS: 472 JPY (-8.7% YoY).

Management Guidance (CER Basis):

• Core Revenue: Low-single digit % decline.
• Core Operating Profit: 5% to 8% decline.
• Core EPS: Mid-teens % decline.

Risks and Contingencies:

• FX Volatility: Significant reliance on foreign exchange rates; depreciation of the yen boosted reported revenue but masked underlying flatness.
• Restructuring Costs: Ongoing transformation program costs impacting operating expenses.
• Tax Uncertainty: Reassessment of Deferred Tax Assets and international tax provisions.
• Competition: Generic erosion in Neuroscience (VYVANSE) and increased competition in Rare Diseases (TAKHZYRO).

Investor Verification Checklist

• FX Impact: Verify the extent to which reported revenue and profit growth are driven by the weak yen versus organic volume growth (CER metrics show declines).
• Tax Provision: Review the specific details regarding the reassessment of Deferred Tax Assets and the impact on the effective tax rate.
• Restructuring Timeline: Confirm the duration and total expected cost of the transformation program driving the JPY 35.8 billion expense increase.
• Core EPS Decline: Analyze the drivers behind the projected mid-teens decline in Core EPS for the full year despite revenue growth.
• Dividend Policy: Note the projected total dividend of 204 JPY per share for FY2027, an increase from the prior year's 200 JPY.